Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Trial ID or NCT#

NCT04787991

Status

not recruiting iconNOT RECRUITING

Purpose

This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Official Title

A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

George A Fisher
George A Fisher
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine, Emeritus

Contact us to find out if this trial is right for you.

Contact


650-498-7757

View on ClinicalTrials.gov